Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations
Abstract A study to determine the impact of cyclosporine (Neoral), an inhibitor of P‐gp, on the pharmacokinetics of pralsetinib (trade name GAVRETO®) was conducted in 15 healthy adult volunteers. A single 200 mg dose of pralsetinib was administered orally alone and in combination with cyclosporine w...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2024-06-01
|
| Col·lecció: | Clinical and Translational Science |
| Accés en línia: | https://doi.org/10.1111/cts.13818 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|